Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with chronic lymphocytic leukemia (CLL) in the clinical practice setting, using the informCLL prospective registry.